(Q53269817)

English

Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients.

scientific article published in October 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients. (English)

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

2

object named as

Alloway RR

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

author name string

Stratta RJ

1

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

Lo A

3

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

Hodge EE

4

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

Transplantation Proceedings

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

37

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

8

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

3527-3530

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Chronic rejection: the next major challenge for pancreas transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Impact of graft failure on patient survival on dialysis: a comparison of transplant-naive and post-graft failure mortality rates

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.09.061

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2005.09.061

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/16298650

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53269817&oldid=2069680732"